neurocutaneous syndromes

The answer first

The neurocutaneous syndromes (the phakomatoses) are a group of autosomal dominant tumour-suppressor disorders in which the skin, eye and nervous system are linked by a shared embryological origin and a unifying pathobiology of aberrant mTOR/RAS signalling. The answer-first physician approach is to recognise the cutaneous stigmata, name the syndrome, and then deliver a programme of syndrome-specific surveillance, complication screening and — increasingly — targeted medical therapy that has transformed a previously expectant speciality into one with active disease-modifying treatment. ^{[1] [3]}

For the FRACP candidate the neurocutaneous long case rewards a tight one-sentence synthesis ("a 28-year-old woman with neurofibromatosis type 1, a symptomatic plexiform neurofibroma and recently diagnosed optic pathway glioma presenting with new hypertension"), a problem list ordered by threat to vision, life and cognition, and a plan that integrates clinical genetics, ophthalmology, neuro-oncology, nephrology and reproductive counselling. ^{[3] [10]} The trap is treating the syndrome label as the diagnosis: each phakomatoses patient is a portfolio of named complications, each with its own threshold and surveillance interval, and the consultant's job is to drive the schedule. ^{[1] [9]}

References13ShowHide

1. [1]Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation Genet Med, 2021.PMID 34012067
2. [2]Gross AM, Wolters PL, Dombi E, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas N Engl J Med, 2020.PMID 32187457
3. [3]Stewart DR, Korf BR, Nathanson KL, et al. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) Genet Med, 2018.PMID 30006586
4. [4]Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial Lancet, 2013.PMID 23158522
5. [5]Franz DN, Belousova E, Sparagana S, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study Lancet Oncol, 2014.PMID 25456370
6. [6]Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial Lancet, 2013.PMID 23312829
7. [7]Goldbrunner R, Weller M, Regis J, et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma Neuro Oncol, 2020.PMID 31504802
8. [8]Yeom S, Comi AM Updates on Sturge-Weber Syndrome Stroke, 2022.PMID 36263782
9. [9]Louise M Binderup M, Smerdel M, Borgwadt L, et al. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance Eur J Med Genet, 2022.PMID 35709961
10. [10]Fisher MJ, Loguidice M, Gutmann DH, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis Neuro Oncol, 2012.PMID 22474213
11. [11]Curatolo P, Nabbout R, Lagae L, et al. Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial Ann Neurol, 2021.PMID 33180985
12. [12]Screnci M, Puechmaille M, Berton Q, et al. Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation J Clin Med, 2024.PMID 39685944
13. [13]Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease N Engl J Med, 2021.PMID 34818478